Eli Noncontrolling Interest In Consolidated Entity from 2010 to 2024
| LLY Stock | USD 755.00 6.99 0.93% |
Noncontrolling Interest In Consolidated Entity | First Reported 2009-06-30 | Previous Quarter 87 M | Current Value 91.8 M | Quarterly Volatility 198.2 M |
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli Lilly's main balance sheet or income statement drivers, such as Depreciation And Amortization of 941.5 M, Interest Expense of 510.2 M or Total Revenue of 35.8 B, as well as many indicators such as Price To Sales Ratio of 16.15, Dividend Yield of 0.0074 or PTB Ratio of 51.15. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
Eli | Noncontrolling Interest In Consolidated Entity |
Latest Eli Lilly's Noncontrolling Interest In Consolidated Entity Growth Pattern
Below is the plot of the Noncontrolling Interest In Consolidated Entity of Eli Lilly and over the last few years. It is Eli Lilly's Noncontrolling Interest In Consolidated Entity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
| Noncontrolling Interest In Consolidated Entity | 10 Years Trend |
|
Noncontrolling Interest In Consolidated Entity |
| Timeline |
Eli Noncontrolling Interest In Consolidated Entity Regression Statistics
| Arithmetic Mean | 138,802,578 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 193.25 | |
| Mean Deviation | 136,817,114 | |
| Median | 75,700,000 | |
| Standard Deviation | 268,234,767 | |
| Sample Variance | 71949.9T | |
| Range | 1.1B | |
| R-Value | 0.27 | |
| Mean Square Error | 71946.1T | |
| R-Squared | 0.07 | |
| Significance | 0.34 | |
| Slope | 16,035,610 | |
| Total Sum of Squares | 1007298.5T |
Eli Noncontrolling Interest In Consolidated Entity History
About Eli Lilly Financial Statements
Eli Lilly investors use historical fundamental indicators, such as Eli Lilly's Noncontrolling Interest In Consolidated Entity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Noncontrolling Interest In Consolidated Entity | 91.8 M | 141.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.